Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 14/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21326698 | 0.86 | PDE2A (0.53) | PDE2AHSD11B1PDE10APDE3A | |
| SCHEMBL19045790 | 0.83 | PDE2A (0.57) | PDE2AHSD11B1KDM4EALDH1A1PDE10A | |
| SCHEMBL17781274 | 0.81 | KDM4E (0.57) | PDE2AKDM4EALDH1A1PDE10APDE3A | |
| SCHEMBL12505413 | 0.80 | IRAK4 (0.43) | PDE2AKDM4EALDH1A1TDP1 | |
| SCHEMBL28667748 | 0.79 | KDM4E (0.41) | PDE2AHSD11B1KDM4EALDH1A1TDP1 | |
| SCHEMBL310362 | 0.79 | HSD11B1 (0.49) | PDE2AHSD11B1KDM4EALDH1A1TDP1 | |
| SCHEMBL309283 | 0.79 | KDM4E (0.43) | PDE2AKDM4EALDH1A1TDP1 | |
| SCHEMBL310187 | 0.79 | KDM4E (0.43) | PDE2AKDM4EALDH1A1TDP1PDE10A | |
| SCHEMBL23728540 | 0.78 | PDE2A (0.43) | PDE2AKDM4EALDH1A1TDP1PDE10A | |
| SCHEMBL359148 | 0.78 | HSD11B1 (0.52) | PDE2AHSD11B1KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2313413-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2011-04-27 | — | — | EP | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| EP-2102211-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | PDE2A 2965/4885HSD11B1 2054/4885KDM4E 2588/4885 |
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | PDE2A 660/4885HSD11B1 4779/4885KDM4E 3426/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | PDE2A 793/4885HSD11B1 86/4885KDM4E 3565/4885 |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE3A, PDE5A | PDE2A 4/4885HSD11B1 1486/4885KDM4E 431/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PDE2A 528/4885HSD11B1 345/4885KDM4E 2800/4885 |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | STING1, MAVS, IRF3 | PDE2A 194/4885HSD11B1 3719/4885KDM4E 2249/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PDE2A 528/4885HSD11B1 345/4885KDM4E 2800/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | PDE2A 2229/4885HSD11B1 2742/4885KDM4E 261/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PDE2A 360/4885HSD11B1 286/4885KDM4E 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.